To the Editor:Acute myeloid leukemia(AML)is a heterogeneous disease characterized by proliferation of abnormal myeloblasts in the bone marrow.Traditional treatment,such as chemotherapy with or without hematopoietic st...To the Editor:Acute myeloid leukemia(AML)is a heterogeneous disease characterized by proliferation of abnormal myeloblasts in the bone marrow.Traditional treatment,such as chemotherapy with or without hematopoietic stem cell transplantation(HSCT),has been used as the first-line therapy in AML.However,the clinical outcome of patients with AML varies greatly due to several factors,such as the tumor immune microenvironment(TME).展开更多
基金National Natural Science Foundation of China(Nos.81670166,81870140,82070184,and 81621001)Peking University People’s Hospital Research and Development Funds(No.RDL2021-01)+1 种基金Beijing Life Oasis Public Service Center(No.CARTFR-01)CSH Young Scholars and 3SBio Pharmaceutical joint research project(No.KYC2201001)
文摘To the Editor:Acute myeloid leukemia(AML)is a heterogeneous disease characterized by proliferation of abnormal myeloblasts in the bone marrow.Traditional treatment,such as chemotherapy with or without hematopoietic stem cell transplantation(HSCT),has been used as the first-line therapy in AML.However,the clinical outcome of patients with AML varies greatly due to several factors,such as the tumor immune microenvironment(TME).
